[go: up one dir, main page]

HUP0105077A2 - Szerin-proteáz inhibitorok és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Szerin-proteáz inhibitorok és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0105077A2
HUP0105077A2 HU0105077A HUP0105077A HUP0105077A2 HU P0105077 A2 HUP0105077 A2 HU P0105077A2 HU 0105077 A HU0105077 A HU 0105077A HU P0105077 A HUP0105077 A HU P0105077A HU P0105077 A2 HUP0105077 A2 HU P0105077A2
Authority
HU
Hungary
Prior art keywords
group
pharmaceutical compositions
factor
compositions containing
protease inhibitors
Prior art date
Application number
HU0105077A
Other languages
English (en)
Inventor
Ignacio Aliagas-Martin
Dean R. Artis
Michael S. Dina
John A. Flygare
Richard A. Goldsmith
Regina A. Munroe
Alan G. Olivero
Richard Pastor
Thomas E. Rawson
Kirk D. Robarge
Daniel P. Sutherlin
Kenneth J. Weese
Aihe Zhou
Yan Zhu
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of HUP0105077A2 publication Critical patent/HUP0105077A2/hu
Publication of HUP0105077A3 publication Critical patent/HUP0105077A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A találmány tárgyát az (I) általános képletű vegyületek képezik,amelyek szerin-proteáz enzimek (szöveti faktor (TF)/VIIa-faktor, VIIa-faktor, Xa-faktor, trombin és/vagy kallikrein) inhibitorai, éselőnyösen alkalmazhatók véralvadási rendellenességek megelőzéséreés/vagy kezelésére. Szintén a találmány tárgyát képezik az evegyületeket tartalmazó készítmények. A képletben <A< és <B< jelentéseegymástól függetlenül CH-csoport, CR3-csoport vagy nitrogénatom; Xjelentése C=O-; Y jelentése S(O)n-R1 csoport; n értéke 1 vagy 2; N1 ésN2 jelentése nirtogénatomok; Q és R1 jelentései: adott esetbenszubsztituált 1-10 szénatomos alkil-, aril-, heteroaril-,karbociklil-, heterociklil-alkil-, 2-10 szénatomos alkenil-,arilalkenilcsoport; R2 jelentése adott esetben szubsztituáltalkilcsoport; R3 jelentése hidrogénatom, 1-6 szénatomos alkilcsoport. Ó
HU0105077A 1999-01-13 2000-01-11 Serine protease inhibitors and pharmaceutical compositions containing them HUP0105077A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11577299P 1999-01-13 1999-01-13
US15202999P 1999-09-01 1999-09-01

Publications (2)

Publication Number Publication Date
HUP0105077A2 true HUP0105077A2 (hu) 2002-05-29
HUP0105077A3 HUP0105077A3 (en) 2005-04-28

Family

ID=26813550

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0105077A HUP0105077A3 (en) 1999-01-13 2000-01-11 Serine protease inhibitors and pharmaceutical compositions containing them

Country Status (19)

Country Link
US (4) US6472393B1 (hu)
EP (1) EP1144373B1 (hu)
JP (1) JP2002534449A (hu)
KR (1) KR100838418B1 (hu)
CN (1) CN100488947C (hu)
AT (1) ATE307111T1 (hu)
AU (1) AU771776B2 (hu)
BR (1) BR0008755A (hu)
CA (1) CA2356934A1 (hu)
CZ (1) CZ20012508A3 (hu)
DE (1) DE60023266T2 (hu)
ES (1) ES2251363T3 (hu)
HU (1) HUP0105077A3 (hu)
IL (2) IL144032A0 (hu)
MX (1) MXPA01007038A (hu)
NO (1) NO20013462L (hu)
NZ (1) NZ512736A (hu)
PL (1) PL350042A1 (hu)
WO (1) WO2000041531A2 (hu)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100838418B1 (ko) * 1999-01-13 2008-06-13 제넨테크, 인크. 세린 프로테아제 억제제
JP4556371B2 (ja) * 1999-09-30 2010-10-06 三菱化学株式会社 アシルスルホンアミド誘導体
DK1383731T3 (da) 2000-10-20 2009-12-07 Biocryst Pharm Inc Biarylforbindelser som serinproteaseinhibitorer
WO2002062829A1 (fr) * 2001-02-02 2002-08-15 Chugai Seiyaku Kabushiki Kaisha Derives de peptide
DE10130374A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Substituierte N-Acyl-anilinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE50310038D1 (de) * 2002-03-11 2008-08-07 Curacyte Ag Hemmstoffe der urokinase, ihre herstellung und verwendung
GB0207637D0 (en) * 2002-04-02 2002-05-15 Karobio Ab Novel compound
AU2003231865A1 (en) * 2002-05-31 2003-12-19 Genzyme Corporation Alpha acyloxyacetamides for kallikrein and urokinase inhibition
DE10301300B4 (de) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
WO2004072102A2 (en) * 2003-02-11 2004-08-26 Bristol-Myers Squibb Company Benzene acetamide compounds useful as serine protease inhibitors
EP1594505A4 (en) * 2003-02-11 2008-08-13 Bristol Myers Squibb Co PHENYLGLYCIN DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS
WO2004113316A1 (en) * 2003-05-20 2004-12-29 Genentech, Inc. Benzofuran inhibitors of factor viia
CA2525854C (en) * 2003-05-20 2009-12-15 Genentech, Inc. Acylsulfamide inhibitors of factor viia
DE10342108A1 (de) * 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
TW200637843A (en) * 2005-01-10 2006-11-01 Bristol Myers Squibb Co Phenylglycinamide derivatives useful as anticoagulants
EP2537520A1 (en) 2005-03-29 2012-12-26 Biocryst Pharmaceuticals, Inc. Hepatics C therapies
US7964619B2 (en) * 2005-06-03 2011-06-21 The University Of North Carolina At Chapel Hill Teraryl components as antiparasitic agents
US8101636B2 (en) * 2005-06-03 2012-01-24 The University Of North Carolina At Chapel Hill Linear dicationic terphenyls and their aza analogues as antiparasitic agents
WO2007002313A2 (en) * 2005-06-24 2007-01-04 Bristol-Myers Squibb Company Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
EP2000465B1 (en) 2006-03-24 2010-12-15 Eisai R&D Management Co., Ltd. Triazolone derivative
US7776832B2 (en) 2006-04-21 2010-08-17 Gem Pharmaceuticals, Llc Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
TW200831080A (en) * 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
PL2114980T3 (pl) 2007-01-12 2012-11-30 Biocryst Pharm Inc Przeciwwirusowe analogi nukleozydów
NZ608343A (en) 2007-04-13 2014-09-26 Southern Res Inst Anti-angiogenic agents and methods of use
JP2010535240A (ja) * 2007-07-31 2010-11-18 マリンクロッド・インコーポレイテッド 一体化光活性薬剤およびその使用
JPWO2009038157A1 (ja) 2007-09-21 2011-01-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 ２，３−ジヒドロ−イミノイソインドール誘導体
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
WO2010036407A2 (en) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
CA2753282C (en) 2009-03-10 2017-11-28 Med Discovery Sa Use of serine protease inhibitors in the treatment of neutropenia
TW201206905A (en) 2010-05-20 2012-02-16 Eisai R & Amp D Man Co Ltd Prodrug of triazolone compound
EP2590945B1 (en) 2010-07-07 2014-04-30 The Medicines Company (Leipzig) GmbH Serine protease inhibitors
WO2013166276A1 (en) 2012-05-02 2013-11-07 Southern Research Institute Triazolopyridazine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof
EP3104706B1 (en) 2014-02-11 2022-03-23 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
CN108934162A (zh) 2015-12-16 2018-12-04 南方研究所 吡咯并嘧啶化合物、作为激酶lrrk2抑制剂的用途及其制备方法
US11001586B2 (en) 2016-11-17 2021-05-11 The University Of North Carolina At Chapel Hill Alkyl pyrrolopyrimidine analogs and methods of making and using same
US10450263B2 (en) 2017-02-10 2019-10-22 Southern Research Institute Benzo annulenes as antiviral agents
US11160826B1 (en) 2017-03-03 2021-11-02 United States Government As Represented By The Department Of Veterans Affairs Cholesterol lowering drugs for the treatment of hepatic encephalopathy
CA3067695A1 (en) 2017-06-21 2018-12-27 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
CA3080193A1 (en) 2017-10-26 2019-05-02 Southern Research Institute Dipeptide analogs as tgf-beta inhibitors
AU2018357933B2 (en) 2017-10-31 2019-11-21 Southern Research Institute Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors
BR112020019183A2 (pt) 2018-04-06 2021-01-05 Biocryst Pharmaceuticals, Inc. Benzofurano, benzopirrol, benzotiofeno substituídos e inibidores de complemento estruturalmente relacionados
WO2019204637A1 (en) 2018-04-19 2019-10-24 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
CN113365614A (zh) 2018-10-02 2021-09-07 由退伍军人事务部代表的美国政府 作为神经保护剂的spak激酶抑制剂
US20220251134A1 (en) 2019-06-14 2022-08-11 Southern Research Institute 2,4,7-substituted-7-deaza-2'-deoxy-2'-fluoroarabinosyl nucleoside and nucleotide pro-drugs and uses thereof
JP2022548907A (ja) 2019-09-17 2022-11-22 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション ベンズイミダゾールおよびそれを使用する方法
EP4069270A4 (en) 2019-12-04 2024-01-03 Southern Research Institute LIGAND 1 PROGRAMMED DEATH AND/OR LIGAND 2 PROGRAMMED DEATH MODULATORS
EP4125845A4 (en) 2020-04-02 2024-05-15 Southern Research Institute NEW 2-PYRIMIDONE ANALOGUES AS EFFECTIVE ANTIVIRAL AGENTS AGAINST ALPHAVIRES
AR121715A1 (es) 2020-04-03 2022-06-29 Biocryst Pharm Inc Pirrolopirimidinaminas como inhibidores del sistema del complemento
EP4146627A4 (en) 2020-04-30 2024-06-19 United States Government as represented by the Department of Veterans Affairs Krüppel-like factor 15 (klf15) small molecule agonists in kidney disease
US11753374B2 (en) 2020-11-18 2023-09-12 Southern Reserach Institute Compounds for the treatment of acute and chronic kidney disease
US11623918B2 (en) 2020-11-18 2023-04-11 Southern Research Institute Compounds for the treatment of acute and chronic kidney disease
CA3235405A1 (en) 2021-10-26 2023-05-04 Omar MOUKHA-CHAFIQ Development of novel clofarabine analogs for cancer therapy
US11905306B2 (en) 2021-12-21 2024-02-20 Southern Research Institute Substituted phenyl ethynyl pyridine carboxamides as potent inhibitors of SARS virus
EP4469465A1 (en) 2022-01-27 2024-12-04 TriLink BioTechnologies, LLC Trinucleotide cap analogs and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA928276B (en) 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
DE4342154A1 (de) * 1993-12-10 1995-06-14 Behringwerke Ag Amidinophenylalaninderivate, Verfahren zu deren Herstellung, deren Verwendung und diese enthaltende Mittel als Antikoagulantien
ES2193202T3 (es) 1994-12-02 2003-11-01 Yamanouchi Pharma Co Ltd Nuevo derivado de amidinonaftilo o sal de este.
ATE251141T1 (de) * 1995-03-10 2003-10-15 Berlex Lab Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
AU3496297A (en) * 1996-06-25 1998-01-14 Eli Lilly And Company Anticoagulant agents
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
TW542822B (en) * 1997-01-17 2003-07-21 Ajinomoto Kk Benzamidine derivatives
AU6896398A (en) * 1997-04-14 1998-11-11 Cor Therapeutics, Inc. Selective factor xa inhibitors
NZ500353A (en) * 1997-04-14 2002-02-01 Cor Therapeutics Inc Cyclic diaza compounds that are selective inhibitors of factor Xa
EP0975659A1 (en) * 1997-04-14 2000-02-02 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
WO1998046591A1 (en) * 1997-04-14 1998-10-22 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
DE19718181A1 (de) * 1997-04-30 1998-11-05 Boehringer Ingelheim Pharma Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
KR100838418B1 (ko) * 1999-01-13 2008-06-13 제넨테크, 인크. 세린 프로테아제 억제제

Also Published As

Publication number Publication date
CN100488947C (zh) 2009-05-20
US20050186198A1 (en) 2005-08-25
WO2000041531A3 (en) 2001-08-16
EP1144373A3 (en) 2002-01-02
JP2002534449A (ja) 2002-10-15
NO20013462L (no) 2001-09-12
BR0008755A (pt) 2007-05-29
ES2251363T3 (es) 2006-05-01
DE60023266D1 (de) 2005-11-24
KR100838418B1 (ko) 2008-06-13
PL350042A1 (en) 2002-10-21
EP1144373B1 (en) 2005-10-19
US6919369B2 (en) 2005-07-19
IL144032A (en) 2006-06-11
US6472393B1 (en) 2002-10-29
NZ512736A (en) 2003-11-28
EP1144373A2 (en) 2001-10-17
US20030212071A1 (en) 2003-11-13
CN1342139A (zh) 2002-03-27
AU771776B2 (en) 2004-04-01
AU3345100A (en) 2000-08-01
CA2356934A1 (en) 2000-07-20
WO2000041531A2 (en) 2000-07-20
DE60023266T2 (de) 2006-07-13
KR20010101852A (ko) 2001-11-15
MXPA01007038A (es) 2002-07-30
ATE307111T1 (de) 2005-11-15
CZ20012508A3 (cs) 2002-02-13
HUP0105077A3 (en) 2005-04-28
NO20013462D0 (no) 2001-07-12
US20070037813A1 (en) 2007-02-15
IL144032A0 (en) 2002-04-21

Similar Documents

Publication Publication Date Title
HUP0105077A2 (hu) Szerin-proteáz inhibitorok és ezeket tartalmazó gyógyszerkészítmények
PT1280797E (pt) Inibidores da peptidase iv de dipeptidilo
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
IS7325A (is) alfa-(N-súlfonamíðó)acetamíð afleiður sem beta-amýlóíð tálmar
HUP0104867A2 (hu) Gyulladásos betegségek kezelésére használható heterociklusos vegyületek, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
EP1248612A4 (en) NEW SUBSTANCES AND COMPOUNDS AS PROTEASE INHIBITORS
SG146658A1 (en) Haloalkyl containing compounds as cysteine protease inhibitors
BRPI0410456A (pt) compostos inibidores de hepatite c, composição farmacêutica, uso dos mesmos, bem como artigo de fabricação
HUP0100669A2 (hu) Szerin proteázokat gátló peptidszármazékok és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
HUP0400456A2 (hu) Hepatitis C vírus N-ciklikus P2 csoportokat tartalmazó makrociklusos NS3-szerin proteáz inhibitorai és ezeket tartalmazó gyógyszerkészítmények
HUP0302962A2 (hu) Béta-karbolinszármazékok, ezeket a vegyületeket tartalmazó gyógyászati készítmények és a vegyületek alkalmazása
MY119155A (en) New peptide derivatives
ATE464889T1 (de) Medizinische verwendung von hemmern von glutaminyl und glutamatcyclasen
ATE282614T1 (de) Phenylharnstoff und phenylthioharnstoffderivate
TR199800009T1 (xx) Yeni trombin inhibit�rleri, bunlar�n haz�rlanmas� ve kullan�m�.
DE60122750D1 (de) Amidine-inhibitoren der serine-proteasen
HUP0000942A2 (hu) Kinolin- és kinazolinszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek előállítása és alkalmazása
DE60121461D1 (de) Kondensierte pyridoindolderivate
HUP0300994A2 (hu) Pirrolidinszármazékok, eljárás előállításukra és alkalmazásuk gyógyszerkészítmények előállítására
SE9904129D0 (sv) Novel compounds
MXPA02012409A (es) Derivados de pirrol para tratamiento del sida.
HUP0204354A2 (hu) Új heterociklusos vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DE60031686D1 (de) Pyrazinone, diese verbindungen enthaltende zusammenstellungen
MXPA05014068A (es) Dicetopiperazinas sustituidas y su uso como antagonistas de oxitocina.
ATE402144T1 (de) Pyrrolidin-2-on-derivate als inhibitoren von thrombin und faktor xa

Legal Events

Date Code Title Description
FC4A Lapse of provisional application due to refusal